Review

Is radical cystectomy the gold standard?
  • Binhan Kağan Aktaş
  • Ali Memiş
Bull Urooncol 2013; 12: 1-5
The Risk Stratifications in Non-Muscle Invasive Bladder Cancer: How Much Accurate are the Methods That We Use? A Multi-Directional View
  • Barış Kuzgunbay
  • Yıldırım Bayazıt
Bull Urooncol 2015; 14: 18-22 DOI: 10.4274/uob.275
Is intravesical BCG treatment necessary and/or sufficient?
  • Sinan Ekici
  • Polat Türker
Bull Urooncol 2013; 12: 22-25
Non-Muscle Invasive Bladder Cancer: Diagnosis and Treatment of Highest-Risk Subgroup
  • Yılören Tanıdır
  • İlker Tınay
Bull Urooncol 2015; 14: 50-54 DOI: 10.4274/uob.298
Can Bladder be Preserved with TURB + Chemotherapy instead of Radical Surgery (Can we Preserve the Bladder from Cancer)
  • Cavit Can
Bull Urooncol 2012; 11: 55-57
Neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
  • Aziz Karaoğlu
  • Utku Oflazoğlu
  • Necla Demir
Bull Urooncol 2013; 12: 58-63
Role of Nanoparticles in the Treatment of Noninvasive Bladder Cancer
  • Erem Bilensoy
  • Nazlı Erdoğar
  • Aydın N. Mungan
Bull Urooncol 2015; 14: 61-66 DOI: 10.4274/uob.246
Which Treatment Should We Prefer for High-Risk Nonmuscle Invasive Bladder Cancer? Early Cystectomy or Bladder Sparing?
  • Ali Furkan Batur
  • Sinan Sözen
Bull Urooncol 2014; 13: 93-98 DOI: 10.4274/UOB.07
The Approach to High Risk Bladder Cancers in The Absence of Bacillus Calmette Guérin: What should Be the Treatment and Follow Up?
  • Polat Türker
  • Levent Türkeri
Bull Urooncol 2014; 13: 103-108 DOI: 10.4274/UOB.09
Hexyl Aminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis of Patients with Non-Muscle Invasive Bladder Cancer: A Review Based on Meta-Analysis
  • Emre Tüzel
Bull Urooncol 2014; 13: 113-118 DOI: 10.4274/UOB.11

Original Article

Predicting Lamina Propria Invasion in Patients with Nonmuscle- invasive Bladder Cancer: Do RDW and NLR Really Work?
  • Aykut Buğra Şentürk
  • Musa Ekici
  • Cemil Aydın
  • Mehmet Murat Baykam
  • Tuncay Taş
  • Ersan Arda
  • Basri Çakıroğlu
Bull Urooncol 2019; 18: 6-9 DOI: 10.4274/uob.galenos.2018.1099
5-Hydroxyuracil Incision Activity Varies According to the Histological Grade of Non-muscle-invasive Bladder Cancer
  • Selçuk Keskin
  • Fatma Merve Antmen
  • Berna Somuncu
  • Yeşim Sağlıcan
  • Tünkut Doğanca
  • Can Öbek
  • Ümit İnce
  • Ali Rıza Kural
  • Meltem Müftüoğlu
Bull Urooncol 2021; 20: 45-48 DOI: 10.4274/uob.galenos.2021.2021-1-8
Evaluation of the Side Effect Profile of Intracavitary Bacillus Calmette-Guérin Treatment in Non-muscle-invasive Bladder Cancer
  • Şenol Tonyalı
  • Mustafa Karaaslan
  • Mehmet Yılmaz
  • Cavit Ceylan
Bull Urooncol 2018; 17: 120-123 DOI: 10.4274/uob.1001
Influence of Primary or Secondary Muscle Invasive Bladder Cancer on Oncologic Outcomes After Radical Cystectomy
  • Serdar Çelik
  • Anıl Eker
  • Ertuğrul Şefik
  • İbrahim Halil Bozkurt
  • İsmail Basmacı
  • Bülent Günlüsoy
  • Tansu Değirmenci
Bull Urooncol 2020; 19: 186-190 DOI: 10.4274/uob.galenos.2019.1288

Article - Comment

Treatment delay and prognosis in invasive bladder cancer
  • Sertaç Yazici
Bull Urooncol 2006; 5: 21-22

Original Articles

The Incidence of Prostate Adenocarcinoma in Patients Who Underwent Cystoprostatectomy for Invasive Baldder Cancer and Histopathological Examination
  • Yasin Ceylan
  • Volkan Şen
  • Salih Polat
  • Bülent Günlüsoy
  • Tansu Değirmenci
  • Yusuf Kadir Topçu
  • Deniz Bolat
  • Zafer Kozacıoğlu
Bull Urooncol 2016; 15: 61-64 DOI: 10.4274/uob.647
Mycobacterium Brumae Extract Fractions with Potential Immunotherapeutic Activity for Bladder Cancer
  • Zeliha Ertürk
  • Esra Büber
  • Haluk Özen
  • Ömür Çelikbıçak
  • Bekir Salih
  • N. Leyla Açan
Bull Urooncol 2017; 16: 70-76 DOI: 10.4274/uob.905

Medical Oncology

Neoadjuvant chemotherapy in muscle invasive bladder cancer
  • Evren Süer
  • Kadir Türkölmez
Bull Urooncol 2012; 11: 74-78